Business Wire

Entrust Datacard Makes Strategic Investment in UK-Based CensorNet and Acquires its Multi-Factor Authentication Technology Solution

Del

Entrust Datacard, a leading provider of trusted identity and secure transaction technology solutions, today announced that it has made a strategic investment in CensorNet, the complete cloud security company, to propel Entrust Datacard toward achieving real-time threat awareness with enhanced pattern analysis for continuous authentication capabilities. Entrust Datacard has also acquired Copenhagen-based SMS Passcode, CensorNet’s adaptive multi-factor authentication technology solution. The strategic acquisition of the SMS Passcode technology and the investment in CensorNet’s USS platform further establishes Entrust Datacard as an innovative authentication solution provider and allows the company to further expand its global footprint throughout DACH/Benelux and The Nordics.

CensorNet’s USS platform, which includes a cloud access security broker (CASB), multi-factor authentication, and web and email security, will bolster new offerings for Entrust Datacard across authentication, PKI and SSL. Additionally, the collaboration will enhance the Entrust Datacard intelligent Authentication Insight Engine by accelerating its behavior and pattern capabilities for more real-time, intelligent decision-making, improving security and the user experience for the next generation of threats and compliance needs.

“Identity-centric data analysis is in CensorNet’s DNA, and identity assurance capabilities in ours,” said Todd Wilkinson, president and CEO for Entrust Datacard. “This new relationship and investment in CensorNet presents opportunities for collaboration to enhance both companies’ offerings and re-shape the market together.”

For greater collaboration between the companies, Entrust Datacard CEO Todd Wilkinson will join CensorNet’s board of directors and the SMS Passcode team will integrate with the larger Entrust Datacard authentication team.

In a quickly-changing IT and threat landscape, the need for a more seamless, frictionless and secure customer experience has never been greater. The acquisition of SMS Passcode will allow Entrust Datacard to better serve customers by integrating the solution’s technology with its IntelliTrust SaaS authentication solution, expanding USS capabilities to Entrust Datacard customers while adding advanced mobile and cloud capabilities to SMS Passcode customers.

“CensorNet and Entrust Datacard have a shared vision for real-time identity centric security that can be achieved faster and with greater impact together rather than separately,” said Ed Macnair, CEO for CensorNet. “The acquisition of SMS Passcode will benefit the broader IAM market as well as SMS Passcode customers, and this new relationship will continue serving customers as Entrust Datacard builds upon existing partnerships and enhances our USS offering.”

Entrust Datacard has a long history of innovating and expanding both geographically and technologically to provide solutions that reflect changing market conditions. Continuing this approach, the SMS Passcode acquisition and investment in CensorNet’s USS platform represents a significant step toward both a holistic security approach and global presence for the organization. At a time when other security players are going through large, complex mergers or acquiring and shelving smaller innovators, Entrust Datacard is building strong partnerships through targeted investments and acquisitions.

“SMS Passcode is an established multi-factor authentication (MFA) leader in DACH/Benelux and The Nordics, making it a natural fit for our acquisition strategy,” said Wilkinson. “The MFA technology, as well as the USS platform, will be strong complements to the Entrust Datacard portfolio of solutions.”

The acquisition was signed and finalized on June 30, 2018. Terms of the acquisition are undisclosed.

For more information about Entrust Datacard’s authentication solutions, visit: https://www.entrustdatacard.com/products/categories/authentication.

About Entrust Datacard Corporation

Consumers, citizens and employees increasingly expect anywhere-anytime experiences — whether they are making purchases, crossing borders, accessing e-gov services or logging onto corporate networks. Entrust Datacard offers the trusted identity and secure transaction technologies that make those experiences reliable and secure. Solutions range from the physical world of financial cards, passports and ID cards to the digital realm of authentication, certificates and secure communications. With more than 2,200 Entrust Datacard colleagues around the world, and a network of strong global partners, the company serves customers in 150 countries worldwide. For more information, visit www.entrustdatacard.com.

About CensorNet

CensorNet, the complete cloud security company, helps organizations to effectively manage and control the use of cloud applications in their business. The company provides a unified and multi-layered approach to securing the cloud via its purpose built, multi-functional cloud security platform that delivers integrated web security, email security, CASB and adaptive multi-factor authentication. This provides organizations with security-focused visibility and control over user access, data and assets to allow access while controlling outcomes and allows organizations to address the security, audit, compliance and productivity issues associated with the use of cloud applications and devices. CensorNet enables organizations to control Shadow IT, safely implement BYOD initiatives and protect from cyber threats. With more than 4000 customers and over 1.3 million users worldwide, the company is headquartered in Basingstoke, UK and has further offices in Austin, US; Copenhagen, Denmark and Munich, Germany. For more information, visit www.censornet.com

Contact information

Entrust Datacard Contact:
Heather Morris, +1 952.988.1745
Director, Global Communications
heather.morris@entrustdatacard.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

In the Wake of the Ongoing Floods in Kerala; UAE Exchange and Unimoni Waive Service Fee on Remittances to Kerala Chief Minister's Distress Relief Fund16.8.2018 09:30Pressemelding

Leading money transfer, foreign exchange and payment solutions brands, UAE Exchange and Unimoni, have waived service fee on remittances to Kerala Chief Minister's Distress Relief Fund in the wake of the catastrophic floods that has ravaged the Indian state of Kerala. The initiative which enables the global Indian diaspora to contribute to the relief efforts, follows a personal contribution of two crore rupees made by the Group Chairman and noted UAE-based businessman and philanthropist, Dr. Bavaguthu Raghuram Shetty, to help those affected by the floods. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180816005229/en/ Promoth Manghat, Executive Director, Finablr and Group CEO (Photo: AETOSWire) Promoth Manghat, Executive Director, Finablr and Group CEO, said, “As a committed corporate citizen, who firmly believes in helping communities in times of need, it was our responsibility to do all that is in our power to aid the peopl

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00Pressemelding

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05Pressemelding

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40Pressemelding

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37Pressemelding

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43Pressemelding

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.